Jagsonpal Pharmaceuticals Ltd. (IN:JAGSNPHARM)
:JAGSNPHARM
Top Page
Jagsonpal Pharmaceuticals Ltd.
(JAGSNPHARM)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹209.00
▲(8.01% Upside)
Action:ReiteratedDate:10/25/25
Jagsonpal Pharmaceuticals Ltd. shows strong financial health with consistent growth and profitability, which is the most significant factor in its stock score. However, technical indicators reflect a bearish trend, and the valuation is moderate with limited dividend appeal. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Revenue & Profitability
Consistent revenue growth and healthy gross and net margins indicate durable demand for the company’s branded formulations and disciplined cost control. Over a multi-quarter horizon this supports reinvestment in sales, stable operating leverage, and persistent earnings power.
Negative Factors
Declining Cash Reserves
Eroding cash buffers undermine short-term liquidity and limit the firm’s ability to absorb shocks or seize opportunistic investments. Over several quarters this may force reliance on working-capital lines or constrain discretionary spending, raising financing risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Profitability
Consistent revenue growth and healthy gross and net margins indicate durable demand for the company’s branded formulations and disciplined cost control. Over a multi-quarter horizon this supports reinvestment in sales, stable operating leverage, and persistent earnings power.
Read all positive factors
Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹12.91B
Dividend Yield1.24%
Average Volume (3M)3.85K
Price to Earnings (P/E)28.8
Beta (1Y)1.00
Revenue Growth24.60%
EPS Growth153.56%
CountryIN
Employees1,025
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.64
Shares Outstanding66,962,250
10 Day Avg. Volume3,534
30 Day Avg. Volume3,854
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)6.09
Price to Sales (P/S)5.44
P/FCF Ratio26.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Jagsonpal Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and c...
How the Company Makes Money
Jagsonpal Pharmaceuticals primarily makes money by selling pharmaceutical formulations (finished dosage medicines) in the Indian market. Revenue is generated when the company markets its branded products to prescribers (e.g., doctors) and fulfills...
Jagsonpal Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
82
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.83B | 2.69B | 2.09B | 2.37B | 2.18B | 1.88B |
| Gross Profit | 1.80B | 1.72B | 652.59M | 1.44B | 1.28B | 1.07B |
| EBITDA | 862.81M | 510.71M | 323.46M | 363.96M | 284.53M | 234.72M |
| Net Income | 619.42M | 553.61M | 224.63M | 267.21M | 188.55M | 170.58M |
Balance Sheet | ||||||
| Total Assets | 2.99B | 2.78B | 2.17B | 1.95B | 1.68B | 1.64B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 1.29B | 1.48B | 1.15B | 472.77M | 618.82M |
| Total Debt | 88.36M | 92.39M | 89.41M | 60.01M | 52.47M | 67.88M |
| Total Liabilities | 461.88M | 383.10M | 296.76M | 360.56M | 375.99M | 422.73M |
| Stockholders Equity | 2.53B | 2.40B | 1.87B | 1.59B | 1.31B | 1.22B |
Cash Flow | ||||||
| Free Cash Flow | 245.77M | 549.52M | 349.18M | 463.37M | 51.31M | 277.53M |
| Operating Cash Flow | 246.75M | 553.00M | 351.66M | 466.54M | 55.98M | 282.22M |
| Investing Cash Flow | -82.07M | -451.47M | -245.48M | -576.71M | -257.79M | -22.64M |
| Financing Cash Flow | -148.90M | -116.98M | -89.11M | -4.57M | -175.52M | -68.28M |
Jagsonpal Pharmaceuticals Ltd. Technical Analysis
Positive
193.50
Price Trends
177.23
Positive
187.42
Positive
211.34
Negative
Market Momentum
3.90
Negative
67.29
Neutral
74.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JAGSNPHARM, the sentiment is Positive. The current price of 193.5 is above the 20-day moving average (MA) of 185.14, above the 50-day MA of 177.23, and below the 200-day MA of 211.34, indicating a neutral trend. The MACD of 3.90 indicates Negative momentum. The RSI at 67.29 is Neutral, neither overbought nor oversold. The STOCH value of 74.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JAGSNPHARM.
Jagsonpal Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹11.54B | 8.47 | ― | 0.37% | ― | ― | |
72 Outperform | ₹27.36B | 18.57 | ― | 0.28% | 7.51% | 71.81% | |
67 Neutral | ₹12.91B | 28.83 | ― | 1.24% | 24.60% | 153.56% | |
61 Neutral | ₹12.33B | 38.81 | ― | 0.44% | -3.84% | 86.82% | |
60 Neutral | ₹7.70B | 22.95 | ― | 0.48% | -18.86% | -150.92% | |
53 Neutral | ₹10.60B | 20.91 | ― | 0.24% | 13.04% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
192.80
-15.78
-7.57%
IN:BAJAJHCARE
Bajaj Healthcare Ltd
335.65
-242.14
-41.91%
IN:BLISSGVS
Bliss Gvs Pharma Limited
258.65
140.24
118.43%
IN:HESTERBIO
Hester Biosciences Limited
1,450.00
-176.01
-10.82%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
576.10
25.72
4.67%
IN:THEMISMED
Themis Medicare Limited
83.56
-38.99
-31.82%
Jagsonpal Pharmaceuticals Ltd. Corporate Events
Jagsonpal Pharma Discloses Rs 4.82 Crore Tax Demand, Plans Appeal
Mar 13, 2026
Jagsonpal Pharmaceuticals Ltd. has disclosed that it received an income-tax assessment order for assessment year 2024-25 from the Income Tax Department’s Faceless Assessment Unit, leading to a tax demand of Rs. 4.82 crore arising from disall...
Jagsonpal Pharma Grants 1.15 Million Stock Options Under ESOP 2022
Mar 9, 2026
Jagsonpal Pharmaceuticals Ltd. has approved the grant of 1,152,500 employee stock options under its 2022 Employee Stock Option Plan at an exercise price of Rs 139 per option, each convertible into equity shares of Rs 2. The options will vest in fo...
Jagsonpal Pharmaceuticals Allots ESOP Shares, Ups Paid-Up Capital
Mar 9, 2026
Jagsonpal Pharmaceuticals has allotted 71,800 equity shares of Rs. 2 each to eligible employees under its Employee Stock Option Plan 2022, following the exercise of vested options. The newly issued shares, priced at an exercise rate of Rs. 94 with...
Jagsonpal Pharma Publishes Unaudited Q3 and Nine-Month FY25 Results Extracts
Jan 22, 2026
Jagsonpal Pharmaceuticals Ltd. has published newspaper advertisements in the English and Hindi editions of Business Standard containing extracts of its unaudited financial results for the quarter and nine-month period ended 31 December 2025, in co...
Jagsonpal Pharma Board Approves Unaudited Q3 and Nine-Month FY25 Results
Jan 21, 2026
Jagsonpal Pharmaceuticals Ltd. announced that its Board of Directors has approved the unaudited financial results for the quarter and nine-month period ended December 31, 2025. The results, which have undergone a limited review by the company̵...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.